CD44, un régulateur de la croissance et de l’invasion cellulaire

Véronique Orian-Rousseau

doi:doi:10.1051/medsci/2003194405

Accès gratuit

Numéro		Med Sci (Paris) Volume 19, Numéro 4, Avril 2003


Page(s)		405 - 407
Section		Le Magazine : Nouvelles
DOI		http://dx.doi.org/10.1051/medsci/2003194405
Publié en ligne		15 April 2003

Dalchau R, Kirkley J, Fabre JW. Monoclonal antibody to a human braingranulocyte- T lymphocyte antigen probably homologous to the W 3/13 antigen of the rat. Eur J Immunol 1980; 10: 745–9.
Naor D, Sionov RV, Ish- Shalom D. CD44: Structure, function and association with the malignant process. In: Vande Woude GF, Klein G, eds. Advances in cancer research. San-Diego: Academic Press, 1997 : 243–318.
Haynes BF, Telen MJ, Hale LP, Denning SM. CD44: a molecule involved in leukocyte adherence and T-cell activation. Immunol Today 1989; 10: 423–8.
Sherman L, Sleeman J, Herrlich P, Ponta H. Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. Curr Opin Cell Biol 1994; 6: 726–33.
Günthert U, Hofmann M, Rudy S, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65 : 13–24.
Seiter S, Arch R, Reber S, et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993; 177: 443–55.
Tanaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U, Shaw S. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1b. Nature 1993 : 361: 79–82.
Bennett KL, Jackson DG, Simon JC, et al. CD44 isoforms containing exon v3 are responsible for the presentation of heparinbinding growth factor. J Cell Biol 1995; 128: 687–98
Sherman L, Wainwright D, Ponta H, Herrlich P. A splice variant of CD44 expressed in the apical ectodermal ridge presents fibroblast growth factors to limb mesenchyme and is required for limb outgrowth. Genes Dev 1998; 12: 1058–71.
Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 2002; 16: 3074–86.
Birchmeier C, Gherardi E Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 1998; 8: 404–10.
Nestl A, Von Stein OD, Zatloukal K, et al. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res 2001; 61: 1569–77.
Legg JW, Isacke CM. Identification and functional analysis of the ezrin-binding site in the hyaluronan receptor, CD44. Curr Biol 1998; 8: 705–8.
Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 1993; 363: 515–21.
Morrison H, Sherman LS, Legg J, et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 2001; 15: 968–80.

[1] Dalchau R, Kirkley J, Fabre JW. Monoclonal antibody to a human braingranulocyte- T lymphocyte antigen probably homologous to the W 3/13 antigen of the rat. Eur J Immunol 1980; 10: 745–9.

[2] Naor D, Sionov RV, Ish- Shalom D. CD44: Structure, function and association with the malignant process. In: Vande Woude GF, Klein G, eds. Advances in cancer research. San-Diego: Academic Press, 1997 : 243–318.

[3] Haynes BF, Telen MJ, Hale LP, Denning SM. CD44: a molecule involved in leukocyte adherence and T-cell activation. Immunol Today 1989; 10: 423–8.

[4] Sherman L, Sleeman J, Herrlich P, Ponta H. Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. Curr Opin Cell Biol 1994; 6: 726–33.

[5] Günthert U, Hofmann M, Rudy S, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65 : 13–24.

[6] Seiter S, Arch R, Reber S, et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993; 177: 443–55.

[7] Tanaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U, Shaw S. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1b. Nature 1993 : 361: 79–82.

[8] Bennett KL, Jackson DG, Simon JC, et al. CD44 isoforms containing exon v3 are responsible for the presentation of heparinbinding growth factor. J Cell Biol 1995; 128: 687–98

[9] Sherman L, Wainwright D, Ponta H, Herrlich P. A splice variant of CD44 expressed in the apical ectodermal ridge presents fibroblast growth factors to limb mesenchyme and is required for limb outgrowth. Genes Dev 1998; 12: 1058–71.

[10] Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 2002; 16: 3074–86.

[11] Birchmeier C, Gherardi E Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 1998; 8: 404–10.

[12] Nestl A, Von Stein OD, Zatloukal K, et al. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res 2001; 61: 1569–77.

[13] Legg JW, Isacke CM. Identification and functional analysis of the ezrin-binding site in the hyaluronan receptor, CD44. Curr Biol 1998; 8: 705–8.

[14] Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 1993; 363: 515–21.

[15] Morrison H, Sherman LS, Legg J, et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 2001; 15: 968–80.

Prix Nobel 2012